Growth‐rate model predicts in vivo tumor response from in vitro data-Reference-Cited by-同舟云学术

Growth‐rate model predicts in vivo tumor response from in vitro data

Published:2022-07-04 Issue:9 Volume:11 Page:1183-1193
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacom & Syst Pharma

Author:

Diegmiller Rocky¹^ORCID,Salphati Laurent²,Alicke Bruno³,Wilson Timothy R.⁴,Stout Thomas J.⁵,Hafner Marc⁶^ORCID

Affiliation:

1. Department of Chemical and Biological Engineering and Lewis‐Sigler Institute for Integrative Genomics Princeton University Princeton New Jersey USA

2. Department of Drug Metabolism and Pharmacokinetics Genentech Inc. South San Francisco California USA

3. Department of Translational Oncology Genentech Inc. South San Francisco California USA

4. Department of Oncology Biomarker Development Genentech Inc. South San Francisco California USA

5. Department of Product Development Oncology Genentech Inc. South San Francisco California USA

6. Department of Oncology Bioinformatics Genentech Inc. South San Francisco California USA

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12836

Reference49 articles.

1. Determinants of drug delivery and transport to solid tumors

2. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research

3. Prediction of Tumor-to-Plasma Ratios of Basic Compounds in Subcutaneous Xenograft Mouse Models

4. Early Tumor Drug Pharmacokinetics Is Influenced by Tumor Perfusion but not Plasma Drug Exposure

5. Determination of the Free Fraction and Relative Free Fraction of Drugs Strongly Bound to Plasma Proteins

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Computational Modeling of Drug Response Identifies Mutant-Specific Constraints for Dosing panRAF and MEK Inhibitors in Melanoma;Cancers;2024-08-22

2. Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors in melanoma;2024-08-06

3. Pharmacodynamics of Cyclin D1 Degradation in Ovarian Cancer Xenografts with Repeated Oral SHetA2 Dosing;The AAPS Journal;2023-12-12

4. Explaining in-vitro to in-vivo efficacy correlations in oncology pre-clinical development via a semi-mechanistic mathematical model;Journal of Pharmacokinetics and Pharmacodynamics;2023-11-06

5. Metabolomics profiling and chemoresistance mechanisms in ovarian cancer cell lines: Implications for targeting glutathione pathway;Life Sciences;2023-11